Eli Lilly and Company

Key catalysts

• Incretin volume growth

  Continued adoption of Mounjaro and Zepbound can support revenue growth across diabetes and obesity markets.

• Oral GLP-1 expansion

  Regulatory and commercial progress for orforglipron can broaden treatment access beyond injectable therapies.

• Pipeline diversification

  Positive late-stage results and business-development transactions can add growth opportunities outside Lilly's current leading products.

Principal risks

• Product concentration

  Growth increasingly depends on Mounjaro and Zepbound, increasing exposure to competitive, safety, reimbursement or execution setbacks affecting these products.

• Pricing pressure

  Lower realized prices, reimbursement negotiations and government pricing measures can offset prescription-volume growth.

• Development and manufacturing execution

  Pipeline failures, regulatory delays or insufficient manufacturing capacity could constrain anticipated growth.

Lilly reported first-quarter 2026 results, raised full-year guidance and highlighted Mounjaro, Zepbound, orforglipron and broader pipeline progress.

Valuation interpretation

• A growth-oriented valuation depends on continued incretin volume expansion while pricing pressure and manufacturing costs remain controlled.
• Pipeline breadth may justify a premium only when clinical progress converts into approvals and commercially meaningful products.